Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeOne Medicines
BeOne Medicines
Domain Therapeutics SA
OSE Immunotherapeutics
Tomsk National Research Medical Center of the Russian Academy of Sciences
Mina Alpha Limited
CStone Pharmaceuticals
CStone Pharmaceuticals
iTeos Therapeutics
Immune-Onc Therapeutics
Immune-Onc Therapeutics
Centre Hospitalier Universitaire Vaudois
Shanghai Kechow Pharma, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Fochon Pharmaceuticals, Ltd.
Agenus Inc.
Modra Pharmaceuticals
Glycotope GmbH
Invectys
Karus Therapeutics Limited
Kyunghee University Medical Center
Washington University School of Medicine